Milrinone as a rescue therapy for symptomatic refractory cerebral vasospasm in aneurysmal subarachnoid hemorrhage
Author
dc.contributor.author
Romero, C. M.
Author
dc.contributor.author
Morales, D.
Author
dc.contributor.author
Reccius, A.
Author
dc.contributor.author
Mena, F.
Author
dc.contributor.author
Prieto, J.
Author
dc.contributor.author
Bustos, P.
Author
dc.contributor.author
Larrondo, J.
Author
dc.contributor.author
Castro, J.
Admission date
dc.date.accessioned
2019-03-11T12:58:19Z
Available date
dc.date.available
2019-03-11T12:58:19Z
Publication date
dc.date.issued
2009
Cita de ítem
dc.identifier.citation
Neurocritical Care, Volumen 11, Issue 2, 2018, Pages 165-171
Identifier
dc.identifier.issn
15416933
Identifier
dc.identifier.other
10.1007/s12028-008-9048-0
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164874
Abstract
dc.description.abstract
Introduction: Delayed ischemic neurological deficit associated to cerebral vasospasm is the most common cause of sequelae and death that follows the rupture of an aneurysm. The objective of this study was to evaluate the safety and efficacy of intra-arterial Milrinone in patients with symptomatic refractory cerebral vasospasm. Patients and Method: Eight patients diagnosed with aneurysmal subarachnoid hemorrhage who developed symptomatic cerebral vasospasm refractory to conventional medical therapy were enrolled. They received an intra-arterial infusion of Milrinone at a rate of 0.25 mg/min, with a total dose of 10-15 mg. Qualitative evaluation of angiographic response, neurological and systemic complications as well as functional outcome at 3 months were documented. Results: All patients had a significant angiographic response. This was evidenced by a pre-treatment vessel stenosis greater than 70%, that improved to less than 50% after the intra-arterial Milrinone infusion. Three patien